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A substantial body of evidence has accumulated linking an
increased incidence of cardiovascular disease in patients with
acute kidney injury (AKI), chronic kidney disease (CKD), and
end-stage renal disease (ESRD). A multitude of novel risk
factors related to decreased kidney function might interact
with the renal and systemic immune systems involved in
renal injury and repair to participate in accelerated
atherogenesis (Immune inflammation-Renal injury-
Atherosclerosis—the IRA Paradigm). In this review, we will
discuss several of these novel risk factors and present the
potential for the role of the immune-inflammatory system
in accelerated atherosclerosis of kidney disease.
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The extraordinary increase in the frequency of coronary
artery disease in patients who were on dialysis was first noted
in 1974 by Lindner et al.1 in Seattle. The importance of this
observation is underscored by the substantial body of
evidence that has accumulated confirming the increased
incidence of accelerated atherosclerosis and vascular calcifi-
cation in patients with chronic kidney disease (CKD) and
end-stage renal disease (ESRD). More recently, it was
demonstrated that the adjusted hazard ratio for cardiovas-
cular events increases inversely with renal function—2.8- to
3.4-fold with stage 4 and 5 CKD.2 The prevalence of CKD
and ESRD continues to increase in the United States, and in
most patients, early CKD will not progress to ESRD as many
die prematurely of cardiovascular disease first.3,4
In the 1970s, the link between lipids and atherosclerosis
predominated the conceptual thinking regarding the patho-
genesis of atherosclerosis.5 Over the last three decades,
significant evidence has emerged on the role of the immune-
inflammatory system in atherosclerosis. Furthermore, the
connections between CKD and cardiovascular disease are well
established and bidirectional. Numerous traditional and
nontraditional risk factors, operating at least partly through
the immune-inflammatory system, might participate. In this
review, we will address some of the novel immune-
inflammatory mechanisms involved in atherosclerosis in the
general population and in patients with CKD, with a
particular focus on unique risk factors in patients with
reduced kidney function.
BROAD OVERVIEW OF CHRONIC INFLAMMATION
Atherosclerosis is a classic example of a maladaptive chronic
inflammatory response in the vessel wall. The inflammatory
response is integral to tissue healing after challenges from
endogenous and exogenous offending agents and danger
signals. In settings in which repetitive injury occurs or in
which the healing process is incomplete, inflammation
remains unresolved to result in a maladaptive chronic
inflammation.
Acutely, cell (endothelial) injury activates the immune
system through activation of pattern-recognition receptors
such as Toll-like receptors, inflammasomes, the endogenous
ligand for pattern-recognition receptors—the high-mobility
group box 1, and the receptor for advanced glycation end
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products.6 Subsequently, there is an influx of innate immune
cells including monocytes that differentiate into macro-
phages, as well as natural killer (NK) cells, NK T cells (NKT),
and mast cells, followed by cells that belong to an adaptive
immune system that includes T cells, B cells, and regulatory
T cells. Blood monocytes are the most numerous cells
that populate atherosclerotic plaque. T cells, although
fewer in number, may exert a decisive regulatory role on
monocytes.7
Monocytes circulate in the blood, bone marrow, and
spleen. These cells are short-lived and do not proliferate.
During inflammation, they migrate from blood into tissues
and differentiate into dendritic cells (DCs) and macrophages
and perform functions that include phagocytosis of cells and
toxic material, production of cytokines, angiogenesis, and
tissue repair. Two distinct subsets of monocytes are present.
Gr1þ /Ly6Chigh/CCR2þ /CX3CR1low inflammatory mono-
cytes (CD14þ /CD16low in humans) can differentiate into
Tip-DC, M1-type, or classically activated macrophages
that mediate inflammation and proteolysis, and Gr1/
Ly6Clow/CCR2/CX3CR1high monocytes (CD14þ /CD16þ
in humans) patrol the vasculature under the steady state,
but, in response to inflammation, they can differentiate into
M2 type or alternatively activated macrophages and are
involved in wound repair and tissue remodeling.8 Chemo-
kines such as CCR2 and CX3CR1 are important in the release
of monocytes from the bone marrow, monocyte recruitment
to the site of injury, and adhesion to the endothelium.8 A
broad and simplistic overview of cells involved in immune
and inflammatory responses in atherosclerosis is presented in
Figure 1.
INFLAMMATION IN ATHEROSCLEROSIS: A BRIEF HISTORIC
PERSPECTIVE
One of the first suggestions of the role of leukocytes in
atherosclerosis was made in 1958 by Poole and Florey,9 who
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Figure 1 |Broad overview of the cells of innate and adaptive immune systems that participate in the pathogenesis of
atherosclerosis. Some of the key functions of these cells are also described. DC, dendritic cell; IL, interleukin; NK; natural killer; NKT, natural
killer T cell; TNF, tumor necrosis factor.
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suggested a potential role of macrophages in atheroma of
rabbits. Accumulation of foam cells derived from phagocy-
tosis of lipids by monocytes and macrophages was demon-
strated in human aortic fatty streaks.10–12 Ross13 suggested an
injury-repair paradigm as a comprehensive mechanism of
atherosclerosis. Although many early studies indicated the
increased presence of immune-inflammatory cells in athero-
sclerosis,14,15 a definite role of leukocytes was not established
until 1980. Schwartz et al.16 suggested a chemotactic role of
vascular smooth muscle cells in attracting circulating
monocytes to the site of atherogenesis, and they proposed
atherosclerosis to be an inflammatory disease. Subsequent
studies have shown accumulation of HLD-DRþ-activated T
cells and macrophages in the intima and adventitia of
atherosclerotic vessels.17,18 Trafficking studies using fluores-
cent labeling techniques confirmed monocyte recruitment to
atherosclerotic arteries.19 Specific roles of the low-density
lipoprotein (LDL) receptor and macrophage scavenger
receptor were subsequently identified.20–23 In the early
1990s, studies evaluated inflammatory cell functions such
as chemotaxis, transmigration of monocytes, cytokine
secretion, and inflammatory cell retention and egress24–26 in
atherosclerosis. The important roles of cytokines and growth
factors such as tumor necrosis factor-a,27 interleukin-12,28
interferon-g,29 platelet-derived growth factor, endothelial
expression of vascular adhesion molecules,30–32 and chemo-
kines33 that could participate in inflammatory cell recruit-
ment were identified. A deficiency of inflammatory-cell
adhesion molecules was shown to protect against athero-
sclerosis in mice.34,35 Intervention studies showing a benefit
of immunosuppressive agents such as steroids and cyclos-
porine indicated a potential role of T cells and cytokines in
experimental atherogenesis.36 Collectively, these studies
initiated an era of expanding investigation into the precise
role of the immune-inflammatory axis in the pathogenesis of
atherosclerosis.
Among leukocytes, polymorphonuclear granulocytes
are rare in atherosclerosis. Adoptive transfer studies with
ApoE//Rag/ double knockouts have confirmed the
importance of T lymphocytes in atherogenesis.37,38 Mono-
cyte-derived macrophages are not only present but also
produce macrophage colony-stimulating factor and prolifer-
ate in response to these growth factors and cytokines.39
Macrophage replication along with failure to undergo
apoptosis results in chronic inflammation.40 Collectively,
these studies have confirmed the importance of innate and
adaptive inflammatory cells in atherogenesis.41,42
NOVEL ASPECTS ON IMMUNITY AND INFLAMMATION IN
ATHEROGENESIS
In this section, we will review the role of novel immune
pathways and inflammatory cell populations that have been
shown to participate in the pathogenesis of atherosclerosis.
Important advances have been made in further delineating
the role of adaptive immunity and the specific role of
inflammatory cell subtypes in atherosclerosis. In the innate
immune system, the role of mast cells, splenic monocytes,
NKT cells, CD11Cþ DCs, and Ly6Chigh/Gr1þ proinflamma-
tory monocytes/macrophages (CX3CR1þ monocyte subset
in humans) has been identified. In the adaptive immune
system, the role for T-regulatory cells, interleukin-17-
producing T cells (TH17 subset), and B cells in athero-
sclerosis has been evaluated.
Role of the innate immune system in atherosclerosis
Monocytes participate critically in atherosclerosis. As discussed
earlier, there are two major subsets that express different
chemokine receptor patterns: Gr1þ /Ly6Chigh/CCR2þ /
CX3CR1low and Gr1/Ly6Clow/CCR2/CX3CR1high mono-
cytes. Both CCR2 and CX3CR1 are linked to progression of
atherosclerotic plaques.43 Atherosclerosis is inhibited by a
selective absence of the monocyte chemokine receptor CCR2 in
ApoE/ mice.44,45 Similarly, ApoE/ mice lacking CX3CL1
or its receptor CX3CR1 have reduced atherosclerosis,46 and
humans with the mutation that results in decreased function of
CX3CR1 and monocyte-adhesion function are relatively
protected from cardiovascular disease.47 Recent studies have
confirmed that blood-monocyte counts were elevated and
skewed toward inflammatory Gr1þ /Ly6Chigh/CCR2þ mono-
cytes in ApoE/ mice fed a high-fat diet. Furthermore,
inflammatory monocytes unexpectedly required CX3CR1 in
addition to CCR2 and CCR5 to accumulate within plaques.
Collectively, these findings point to a central role of CX3CR1
and CCR2 in inflammatory monocyte recruitment in ather-
ogenesis. It is noteworthy that recent studies have uncovered
the spleen as a reservoir of monocytes and have shown it to
participate in rapid deployment of inflammatory monocytes
in response to tissue injury.48 Thus, the spleen as well could
significantly contribute to inflammatory monocytes in
atherosclerosis. However, a note of caution is warranted, as
a small-molecule inhibitor of CCL2 failed to inhibit progres-
sion of atherosclerosis in ApoE/ mice.49
Several studies have shown that mast cells accumulate in
atherosclerotic lesions. In support of their role in the
pathogenesis of atherosclerosis, mast cell-deficient
ApoE//Kit/ mice are protected from atherosclerosis
and susceptibility to atherogenesis is restored by an adoptive
transfer of functional mast cells.50 Mast cells may promote
atherogenesis through their proinflammatory effects50 by
inducing an atherogenic lipid profile, promoting matrix
degradation and endothelial injury, and sustaining vascular
inflammation.51,52
NKT cells are a specialized group of CD1d-restricted
immune cells that share characteristics with both conventional
T cells and NK cells. However, unlike these cells, NKT cells
recognize glycolipid antigens and produce both proinflamma-
tory and anti-inflammatory cytokines upon activation. NKT
cells accumulate in atherosclerosis and represent a bridge
between dyslipidemia and immune regulation. NKT depletion
is protective in animal models of atherosclerosis.53,54
Bobryshev and Lord55 demonstrated accumulation of DCs
in atherosclerosis and suggested their role. Subsequently,
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several studies have identified a potential role of DCs in
atherogenesis, plaque destabilization, and rupture.56 In an
LDL receptor (/) background, intimal DC depletion with
diphtheria toxin during 5 days of lesion formation reduced
the intimal lipid area by 55% relative to undepleted
controls.57 Induction of hypercholesterolemia in mice
triggered rapid ingestion of lipids by resident intimal DCs
to initiate foam-cell formation. Transmission electron
microscopy revealed few foam cells in DC-depleted mice.
Collectively, these studies point to an important role of DCs,
the most potent antigen-presenting cells in the body, in
atherosclerosis.58 Regression of atherosclerosis in cross-
transplantation of arterial segments from ApoE/ mice into
wild-type normolipidemic mice and dependence of regres-
sion on CCR7þ -dependent emigration of CD68þ DCs and
macrophages59 lend further support to the role of DCs and
macrophages.
Role of the adaptive immune system in atherosclerosis
Hansson, in 1985, showed that many of the monocyte-
derived macrophages in atherosclerotic lesions expressed
HLA-DR, a major histocompatibility complex class II protein
required for antigen presentation, to CD4þ T cells.60 The
abundant HLA-DR expression in the plaque suggested
evidence of an active immune-inflammatory reaction in the
atherosclerotic process. Witztum and coworkers reported that
oxidized LDL (oxLDL), which is present in lesions, triggered
antibody production.61 This led to isolation and cloning of T
cells from human carotid lesions and, when exposed to
potential antigens, certain clones were activated by oxLDL.62
CD4þ T cells harvested from wild-type donor mice
immunized with an oxidized form of LDL caused a dramatic
increase in atherosclerotic lesions when introduced into
immunodeficient ApoE/ /SCID/ mice.63 These data
provided direct evidence that the cellular immune response
to a modified LDL antigen has a crucial role in atherogenesis.
Contradicting these findings, several initial studies have
indicated a protective role of B cells and anti-oxLDL antibody
generated by splenic B cells.64 In fact, a study reported that
pneumococcal vaccination, by molecular mimicry, induces
profound increase in IgM anti-oxLDL antibody and pro-
tected LDLR/ mice from atherosclerosis.65,66 However,
over the last few years, we have come to understand that anti-
oxLDL antibodies are a heterogeneous group of autoanti-
bodies including both pathogenic and protective subsets.67,68
Oxidation-specific epitopes are dominant targets of natural
IgM antibodies, indicating an important role for natural IgM
in their clearance and neutralization of their proinflamma-
tory properties. Natural antibodies are mostly antibodies of
the IgM isotype with specificity for both microbial and
altered self-antigens.
In two recent studies, mature B-cell depletion using a
CD20-specific monoclonal antibody induced a significant
reduction of atherosclerosis in various mouse models of the
disease,69,70 and adoptive transfer of a B2 population of B
cells aggravated atherosclerosis.70 CD20-specific monoclonal
antibody treatment preserved the production of protective
anti-oxLDL IgM autoantibodies over IgG-type anti-oxLDL
antibodies and markedly reduced pathogenic T-cell activa-
tion.71 In another pivotal advance, it was shown that CD4þ
T cells recognize epitopes on native ApoB100 protein
associated with a limited set of clonotypic T-cell receptors,
and blocking T-cell receptor-dependent antigen recognition
protected against atherosclerosis. These results strongly
suggest that B cells and autoimmune T cells that recognize
native ApoB100 protein epitopes promote atherosclerosis.72
Autoreactivity is eliminated by central tolerance during
development or avoided by peripheral tolerance mechanisms
that rely on active inhibition of autoreactivity by regula-
tory T cells71 and by inhibiting LDL-reactive Th1 cells.73
Collectively, these studies have provided strong evidence for
the role of adaptive immunity in the pathogenesis of
atherosclerosis.
ATHEROSCLEROSIS IN CKD: NOVEL IMMUNE AND
INFLAMMATORY RISK FACTORS
Several studies have identified the role of traditional and
nontraditional risk factors (such as hypertension, diabetes
mellitus, smoking, elevated LDL cholesterol, low high-density
lipoprotein (HDL) cholesterol, homocysteine, advanced
glycation end products, asymmetric dimethyl arginine, and
uremic toxins such as indoxyl sulfate) in vascular diseases
associated with CKD.74–76 In this review, we will not present
these details again but will discuss immune-inflammatory
changes in CKD and uremia (Figure 2), review the potential
role of some novel risk factors such as klotho, modified
lipoproteins (carbamylated LDL and proinflammatory
HDL), cholesterol crystals, inflammasomes, calciprotein
particles, heme, and iron in sustaining inflammation that
could promote atherogenesis. We will also discuss the
potential link of inflammation associated with acute kidney
injury (AKI) and CKD with atherogenesis.
Immune-inflammatory system changes unique to
kidney injury
Both CKD and uremia induce several changes in the innate
and adaptive immune systems and, collectively, they may
have a strong influence on increased atherogenesis and
vascular disease seen in CKD. Progressive CKD and uremia
are associated with deleterious effects on the innate immune
system, such as decreased phagocytic ability, DC depletion
and dysfunction,77–79 and expansion of circulating CD16þ
proinflammatory monocytes.80 There is also proinflamma-
tory activation of macrophages and DCs characterized by
overproduction of cytokines.81 In addition, uremia induces
mast-cell proliferation and increases mast-cell density in
tissues.82,83 Patients with CKD have adaptive immune system
changes due to dysfunction of antigen-presenting cells (that
lead to impaired activation of effector lymphocytes),
lymphopenia with B-cell depletion, and massive expansion
of proinflammatory CD4þ CD28 T cells, which is
attributed to diminished levels of the anti-aging hormone
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klotho and cytomegalovirus antigen exposure (seropositiv-
ity).84–87 Uremia is associated with a dramatic decrease in the
number and suppressive capacity of CD4þ /CD25þ regula-
tory T cells mediated by proteasome inhibition by oxLDL,
leading to cell-cycle arrest and apoptosis.88 Part of the
dysfunction of regulatory T cells may also be related to low
cholesterol levels (which is known to associate paradoxically
with higher cardiovascular mortality in dialysis patients—
reverse epidemiology) as cholesterol components of lipid
rafts are highly expressed in T-regulatory cells and are
essential for their function.89 Uremia also induces proin-
flammatory changes in the adipose tissue,90 and adipose
tissue macrophages might have an important role in
atherogenesis.91 Collectively, increased proinflammatory
monocytes, mast-cell proliferation, T-lymphocyte dysfunc-
tion, and decreased T-regulatory cells might result in an
immune dysfunction that facilitates accelerated atherogenesis
in uremia.
Preliminary studies have indicated decreased protective
anti-oxLDL IgM autoantibodies and their association with
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increased cardiovascular mortality92 in uremia. However, it is
still not well understood whether these immune changes
result in accelerated autoimmunity and pathogenic antibody
production against native and modified lipoprotein antigens.
B-cell depletion of uremia77 might seem contradictory to the
facilitatory role of these cells in atherogenesis found in the
general population.70,71 This might suggest selective altera-
tion in B-cell sub-populations or, alternatively, suggest a
prominent role of innate rather than adaptive immunity in
uremic atherosclerosis.
Cholesterol, modified lipoproteins, and inflammation
LDL modification. There are certain unique lipoprotein
modifications in uremia that may contribute to accelerated
atherosclerosis. A range of studies—including chemical,
cellular, physiological, animal model, and clinical investiga-
tions—support the conclusion that protein carbamylation is a
biochemical pathway intrinsic to inflammation and the
pathophysiology of atherosclerosis. There is a strong and
independent relationship between systemic measures of
protein carbamylation and both coronary artery disease
prevalence and future risks for major adverse cardiac events.93
Carbamylation of proteins confers multiple pro-atherosclero-
tic biological activities, including increased scavenger-receptor
recognition of LDL leading to foam-cell formation,94 en-
dothelial dysfunction, and vascular smooth muscle prolifera-
tion. Recent studies have shown unambiguously that protein
carbamylation is catalyzed by cyanate (a reactive species in
equilibrium with urea and increased in the setting of elevated
blood-urea levels)95 and by the leukocyte heme peroxidase
myeloperoxidase,96 which is increased in uremia. Although
inflammation-driven protein carbamylation is a quantitatively
dominant mechanism for carbamylation in a non-CKD
setting, in the presence of renal dysfunction, it is likely that
both elevated urea and myeloperoxidase contribute to this
process. It was demonstrated by our group that carbamylated
LDL induced by either surgical CKD or oral ingestion of urea
was convincingly shown to accelerate atherosclerosis in
atherosclerosis-prone ApoE/ mice fed a high-fat diet. Oral
administration of urea increased carbamylated LDL approxi-
mately eightfold in ApoE/ mice subjected to unilateral
nephrectomy and fed a high-fat diet. Regardless of the model,
uremic mice with high plasma carbamylated LDL had more
severe atherosclerosis as measured by intravital ultrasound and
en face aortic staining of lipid deposits. Furthermore,
carbamylated LDL accumulated in the aortic wall and co-
localized with intercellular adhesion molecule-1 and macro-
phage infiltration.97,98
HDL modification. During episodes of acute inflamma-
tion, HDL) experiences a major change in apolipoprotein
composition and becomes acute-phase HDL. This altered
HDL has an increased binding affinity for macrophages.
Among the changes are an increase in serum amyloid A
(SAA), secretory phospholipase A (2), platelet-activating
factor acetylhydrolase content, and a decrease in apolipo-
protein A-I, and paraoxonase-1 (PON1). SAA is transported
predominantly on HDL, and levels of this protein increase
markedly during acute and chronic inflammation in both
animals and humans; this has been demonstrated in patients
with CKD as well.99 Recent studies support the proposal that
SAA has a role in atherogenesis.100 Increased SAA levels
predict the risk of cardiovascular disease in mice and
humans.100,101 In uremic mice, the SAA content of HDL3 is
significantly increased.102 Ezetimibe has been shown recently
to decrease the SAA content of HDL3 cholesterol, making
HDL more anti-atherogenic.103 Supporting the potential
clinical importance of this effect, a simvastatin–ezetimibe
combination reduced cardiovascular events in CKD in the
SHARP (Study of Heart and Renal Protection) trial,104,105
whereas rosuvastatin monotherapy (which decreases LDL
cholesterol but is not known to decrease SAA) failed to show
a cardiovascular benefit in dialysis patients in the 4D trial.106
There may be an important role for other HDL-associated
proteins in regulating atherogenesis. For example, there is
recent evidence that suggests that secretory phospholipase
A2, an HDL-associated protein, and platelet-activating factor
acetylhydrolase, a protein associated predominantly with
LDL in humans and with HDL in mice, might also have a role
as both markers and mediators of human atherosclerosis.107
PON1 is atheroprotective in animal models of hypercholester-
olemia. However, studies in uremic patients have been
inconclusive about their role independent of HDL3 levels.108,109
Cholesterol crystals. Cholesterol crystals are a hallmark of
atherosclerosis.110 Recent studies have indicated that choles-
terol crystals accumulate in early atherosclerotic lesions.111
Furthermore, inhibition of Acyl CoA:cholesterol acyltransfer-
ase resulted in increased cardiovascular mortality and was
associated with accumulation of cholesterol crystals.112 Thus,
a crystal form of cholesterol rather than esterified cholesterol
may be important in atherogenesis. Recent studies have
indicated that the crystalline form of cholesterol acts as an
endogenous danger signal and undergoes frustrated phago-
cytosis by macrophages. This process leads to caspase
1-activating NACHT domain-, leucine-rich repeat-, and
PYD-containing protein 3 inflammasome activation to result
in chronic inflammation. Furthermore, mice deficient in
NACHT domain-, leucine-rich repeat-, and PYD-containing
protein 3 and low LDL receptor and fed a high-fat diet had
markedly decreased atherosclerosis.113 Uremic atherosclerosis,
in animal models and in humans, is associated with cholesterol
crystal accumulation in areas proximate to calcification,114,115
and might have an important role in mineralization.116
However, the role of the Nacht domain-, leucine-rich repeat-,
and PYD-containing protein 3 inflammasome in uremic
atherosclerosis or calcification has not been explored.
Calciproteins, inflammation, and atherogenesis in CKD. Calcify-
ing atherosclerosis is an active process more commonly seen in
CKD patients with deranged divalent-mineral metabolism and is
controlled by calcification inhibitors and inducers. Fetuin, an
acute-phase glycoprotein, is a prototype-circulating, calcium-
regulatory glycoprotein that inhibits vascular calcification by
inhibition of hydroxyapatite formation. In a recent study of
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dialysis patients, it was shown that a low fetuin-A level is
associated with malnutrition, inflammation, and atherosclerosis
(carotid plaques), as well as with increased cardiovascular and
all-cause mortality.117 In addition, the combination of fetuin-A
deficiency, a high-phosphate diet, and CKD in ApoE-deficient
mice greatly enhanced atherosclerotic vascular intimal and
myocardial calcification.118 Multicenter cross-sectional and
cohort studies on dialysis patients have confirmed the association
of serum fetuin-A levels with both cardiovascular and non-CV
mortality.119 Fetuin-A develops a complex with calcium and
phosphate and forms a calciprotein particle or fetuin–mineral
complex. Recent data have suggested that fetuin–mineral
complexes or calciprotein particles, rather than serum fetuin-A,
reflects extra-osseous calcification in dialysis patients. Calcipro-
tein particles may have effects on the immune-inflammatory
system akin to modified lipoproteins or cholesterol crystals in
promoting inflammatory calcification in atherosclerosis.120,121
Iron, heme, and inflammation in atherogenesis. Free oxygen
radicals act directly on endothelial cells and induce lipid
peroxidation, causing a modification of LDL and facilitating
LDL deposition, with the consequent formation of athero-
sclerotic plaques. Free-radical production is catalyzed and
accelerated in the presence of iron.122 A possible association
between body-iron status and the risk of coronary heart
disease was first supported by findings from a Finnish study
relating increased levels of both serum ferritin and dietary
iron to an increased risk of myocardial infarction in men.123
However, there are some contrasting studies such as the study
by Ascherio and colleagues that did not support the role of
iron in coronary artery disease. In their study of ApoE-
deficient mice, a 2% carbonyl iron diet did not exacerbate but
rather reduced the severity of atherosclerosis by 50%. This
was despite the fact that there was twice as much iron in their
plasma, a nine-fold increase in bleomycin-detectable free iron
in their plasma, and ten times as much iron in their livers as
control mice.124 These arguments notwithstanding, it is not
surprising that iron status does not reflect susceptibility to
atherosclerosis because it is the iron available to catalyze free-
radical reactions that is very important. This point was nicely
demonstrated in our animal studies a few years ago in which,
in two models of glomerular disease, an iron-deficient diet
was accompanied by a reduction in catalytic iron and was
found to be protective.125 Conversely, an iron-deficient diet
was not protective in ischemia–reperfusion injury, and
animals that had been fed an iron-deficient diet had an
identical amount of catalytic iron in the kidney cortex.126
Thus, iron status per se may not dictate the final effect.
In addition, catalytic iron in the vascular tissue rather than
systemic may be more relevant to atherogenesis. In fact, Juan
et al. showed that young (14-weeks-old) ApoE-deficient mice
that received adenovector-heme oxygenase-1 for 6 weeks
developed significantly smaller lesions in the aorta than did
controls receiving empty viral vector, and iron deposition
and tissue-iron content was much less in the aortic tissue
of mice treated with an adenovirus containing human
HO-1 (Adv-HO1). Thus, overexpression of HO-1 in vascular
cells facilitates tissue-iron disposal and attenuates develop-
ment of atherosclerosis in ApoE-deficient mice.127 Moreover,
the effect of iron might depend on susceptibility of
the host to injury, the inflammatory state of the host, and
net effects of iron on inflammatory cell function. For
example, iron also has been shown to regulate immunity
by regulating macrophage function.128,129 Decreasing intra-
cellular iron by genetic manipulation, hepcidin, or iron
chelation attenuates the proinflammatory function of macro-
phages128 and benefits angiotensin II-induced vascular
dysfunction.130
The role of iron in atherosclerosis becomes particularly
important in patients with reduced kidney function, as
parenteral iron routinely used in these patients has been
suggested to be an additional contributing factor to
cardiovascular disease through its effects on increasing labile
iron, oxidative stress, inflammation, and endothelial dysfunc-
tion,131–133 and serum levels of labile iron are increased in
CKD.134 In addition and importantly, cardiovascular risk
associated with erythropoietin therapy in CKD and ESRD
patients might be related to an increase in tissue iron
mediated by erythropoietin’s suppressive effect on hepcidin
and stimulating effect on iron export.135–137
Recent studies have also shown the importance of vascular
erythrocytes, heme, and iron derived from intraplaque
hemorrhages in the pathogenesis of progressive atherosclero-
sis.138,139 Circulating free heme levels are increased in dialysis
patients due to increased hemolysis, decreased red blood cell
life span, and neocytolysis in the context of intermittent
erythropoietin therapy.140,141 Additional support for the
potential importance of heme metabolism in atherogenesis
comes from studies that have shown an increased risk of
atherosclerosis in the haptoglobin 2–2 (Hp 2–2) phenotype.
An impaired clearance of hemoglobin from plaques in Hp
2–2 individuals results in a higher prevalence of plaque iron
in these individuals.138,142,143 Although studies have sug-
gested a protective effect of the Hp 1–1 phenotype on elderly
patients with ESRD,144 any direct relationship between free
heme levels and cardiovascular events in dialysis patients has
not been examined in detail thus far.
ATHEROGENESIS: LINK TO AKI AND CKD
There is evidence to suggest that atherosclerosis is an episodic
rather than linear process.145 This is analogous to our current
understanding regarding progression of renal disease, in that
episodes of AKI may have a major role in the progression of
CKD.146–149 In addition, AKI has an independent and graded
association with long-term mortality. Patients with mild and
moderate AKI, irrespective of the etiology, had an elevated
risk of death after hospitalization that did not dissipate
over time.150,151 Reasons for this association are unclear and
possibilities include evolution into more severe CKD,146
which then results in increased vascular disease.2 Alterna-
tively, it may be a lasting and perhaps irreversible memory
effect of the AKI itself on nonrenal organs.152 It is of
importance that AKI is an inflammatory disease58,153 and an
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episode of AKI results in durable changes in renal and extra-
renal immune systems. Persistent renal inflammation results
from contributions from innate and adaptive immune cells,58
as well as renal tubular cells.154,155 Raab et al. have shown that
phagocyte and CD4þ T-cell infiltration were significantly
increased in ischemic kidneys. This was accompanied by a
significant increase in cytokines such as interleukin-1b and
regulated upon activation of normal T-cell-expressed and
T-cell-secreted (RANTES) expression. Despite similar splenic
CD4 and CD8 numbers, intracellular cytokine staining of T
cells revealed a significant increase in interferon-g in
ischemia–reperfusion injury mice.156 AKI is associated with
increased hepatic and pulmonary inflammation as well.157,158
It is unknown whether these acute inflammatory changes in
distant organs are completely resolved after AKI recovers or
whether it leads to chronic inflammatory changes, fibrosis,
and clinical or subclinical functional changes that might
contribute to atherosclerosis.159–162 In addition, repeat
episodes of AKI and its associated inflammation (T-cell,
B-cell, and plasma-cell recruitment)163 might result in the
development of secondary and tertiary lymphoid structures
within the kidney which then perpetuates renal and systemic
inflammation.164–167 Thus, it is conceivable that repeat
episodes of AKI might contribute to a more persistent
proinflammatory effect on the immune system that not only
participates in progressive renal dysfunction and CKD but is
also more pro-atherogenic (Immune-inflammation-Renal
injury-Atherosclerosis, or the IRA Paradigm, Figure 2).
CONCLUSIONS
Accelerated atherosclerosis in kidney disease may be related
to several unique and novel risk factors that affect the innate
and adaptive immune system. Repeated episodes of AKI
might thus contribute to a more persistent proinflammatory
state that not only participates in progressive renal dysfunc-
tion and CKD but is also more pro-atherogenic. Prevention
and treatment of AKI and CKD might prove beneficial in the
prevention and treatment of cardiovascular disease in this
population. Insight and more research into these areas,
particularly the immune system and inflammatory pathways,
might yield novel therapeutic approaches.
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